36 active not recruiting. 36 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Active not recruiting 36 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Healthy: new trials by email Literature Review of Healthy trials Research Report on Healthy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity Survodutide formulation A, Survodutide formulation B2 - Healthy, Obesity | Phase 1 | Active not recruiting | Boehringer Ingelheim | 44 | 2026-09-02 | 2026-10-28 |
| A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood BI 3000202, Ciclosporin, Itraconazole - Healthy | Phase 1 | Active not recruiting | Boehringer Ingelheim | 16 | 2026-09-01 | 2026-10-13 |
| A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044) Enlicitide - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 30 | 2026-08-31 | 2026-09-18 |
| A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20 tilrekimig and rHuPH20 - Healthy | Phase 1 | Active not recruiting | Pfizer | 12 | 2026-08-27 | 2026-10-20 |
| A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007) MK-4082 Formulation 1 (F1), MK-4082 Formulation 2 (F2), MK-4082 Formulation 4 (F4) - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 48 | 2026-08-25 | 2026-09-23 |
| A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or Overweight BI 3034701 (C-14) - Healthy | Phase 1 | Active not recruiting | Boehringer Ingelheim | 8 | 2026-08-24 | 2026-10-13 |
| A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight BI 3034701, Placebo - Healthy, Obesity | Phase 1 | Active not recruiting | Boehringer Ingelheim | 48 | 2026-07-21 | 2026-10-01 |
| A Study of LY4268989 (MORF 057) in Healthy Participants LY4268989 - Healthy | Phase 1 | Active not recruiting | Eli Lilly and Company | 50 | 2026-07-20 | 2026-10-08 |
| A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021) MK-8527, Probenecid, Itraconazole - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 44 | 2026-06-30 | 2026-09-03 |
| A Pharmacokinetic Study of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants. Gecacitinib Hydrochloride Tablets - Healthy | Phase 1 | Active not recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 64 | 2026-05-12 | 2026-06-08 |
| Evaluation of the Food Effecton the Pharmacokinetics of FWD1802 in Healthy Subjects FWD1802 - Healthy | Phase 1 | Active not recruiting | Forward Pharmaceuticals Co., Ltd. | 18 | 2026-03-15 | 2026-07-16 |
| A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Formulation A, Formulation B6 - Healthy, Obesity | Phase 1 | Active not recruiting | Boehringer Ingelheim | 80 | 2026-03-11 | 2026-09-09 |
| A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039) MK-0616A, Enlicitide, Rosuvastatin - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 60 | 2025-12-29 | 2026-09-23 |
| A Study of V118E in Healthy Participants (V118E-003) V118E, PREVNAR 20™, Saline - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 126 | 2025-10-08 | 2026-10-23 |
| A Clinical Trial to Evaluate the Effect of Grapefruit Juice on the PK/PD of Edoxaban Edoxaban 60 MG [Lixiana], Edoxaban 60 MG [Lixiana] + Grapefruit Juice - Healthy | Phase 1 | Active not recruiting | Hyewon Chung | 14 | 2025-09-02 | 2025-09-16 |
| A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults PF-07985631, Placebo - Healthy | Phase 1 | Active not recruiting | Pfizer | 26 | 2025-08-13 | 2026-10-30 |
| A Study of LY3981314 in Healthy Participants LY3981314, Placebo - Healthy | Phase 1 | Active not recruiting | Eli Lilly and Company | 76 | 2025-06-09 | 2026-05-19 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants. AZD1613, Placebo - Healthy | Phase 1 | Active not recruiting | AstraZeneca | 72 | 2025-06-06 | 2026-10-05 |
| A Study of LY3867070 in Healthy Participants LY3867070, Placebo - Healthy | Phase 1 | Active not recruiting | Eli Lilly and Company | 196 | 2025-05-27 | 2026-10-06 |
| A Study of SPY003-207 in Healthy Volunteers SPY003-207, Placebo - Healthy | Phase 1 | Active not recruiting | Spyre Therapeutics, Inc. | 59 | 2025-03-10 | 2026-03-20 |
Showing 20 of 36. Sign in to see all of them.
Obesity (4) · Insulin Resistance (1) · Marijuana Abuse (1) · Opioid-Related Disorders (1) · Overweight (1) · Schizophrenia (1) · Staphylococcal Infections (1) · Tuberculosis (1)
Body Weight (4) · Nutrition Disorders (4) · Nutritional and Metabolic Diseases (4) · Overnutrition (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Mental Disorders (3) · Overweight (3) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Chemically-Induced Disorders (2) · Gram-Positive Bacterial Infections (2) · Infections (2) · Substance-Related Disorders (2) · Actinomycetales Infections (1)
Itraconazole (2) · MK-0616 (2) · Sodium Chloride (2) · 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) (1) · Adrenergic alpha-Antagonists (1) · BI 456906 (1) · Carbon-14 (1) · Cyclosporine (1) · F 4 (1) · Ketamine (1) · Loperamide (1) · Mupirocin (1) · Naloxone (1) · Neu1 protein, mouse (1) · Nitroprusside (1)
Merck Sharp & Dohme LLC (6) · Boehringer Ingelheim (5) · Eli Lilly and Company (3) · Pfizer (2) · Alexion Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Brilliant Inspiration Biotherapeutics (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Forward Pharmaceuticals Co., Ltd. (1) · Hyewon Chung (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Latigo Biotherapeutics (1) · New York State Psychiatric Institute (1) · Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) (1) · Spyre Therapeutics, Inc. (1)
United States (17) · China (5) · Australia (2) · Canada (2) · Germany (2) · United Kingdom (2) · Belgium (1) · France (1) · Hungary (1) · Japan (1) · New Zealand (1) · South Africa (1) · South Korea (1)
Deanna Nguyen, MD (1) · Doug Warner, M.D. (1) · Gavin Churchyard, PhD (1) · Jason Wu (1) · Javid Ghandehari, MD (1) · Jordan Schultz, PharmD (1) · Karina A Thiessen, BA BEd (1) · Rasmus Mortensen, PhD (1) · Robert Fishman, MD (1) · Yanmei Liu (1)
R01MH123142 (1)